Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D’Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Don D. Sin & Darcy D. Marciniuk. (2019) Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3:4, pages 210-232.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Darcy D. Marciniuk, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D'Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Denis E. O'Donnell & Don D. Sin. (2017) CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 222-241.
Read now
Read now
Keisaku Fujimoto, Haruna Yamazaki, Midori Ura & Yoshiaki Kitaguchi. (2017) Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 3195-3201.
Read now
Read now
Antonio Anzueto & Marc Miravitlles. (2017) Pathophysiology of dyspnea in COPD. Postgraduate Medicine 129:3, pages 366-374.
Read now
Read now
Denis E. O’Donnell, Katherine A. Webb, Ingrid Harle & J. Alberto Neder. (2016) Pharmacological management of breathlessness in COPD: recent advances and hopes for the future. Expert Review of Respiratory Medicine 10:7, pages 823-834.
Read now
Read now
Charlotte Suppli Ulrik. (2015) Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 16:17, pages 2653-2659.
Read now
Read now
Yu Nishijima, Seigo Minami, Suguru Yamamoto, Yoshitaka Ogata, Taro Koba, Shinji Futami & Kiyoshi Komuta. (2015) Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 439-444.
Read now
Read now
Andrea Rossi, Erika Zanardi, Venerino Poletti & Mario Cazzola. (2015) Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1383-1392.
Read now
Read now
Maria Gabriella Matera, Paola Rogliani & Mario Cazzola. (2015) Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 16:1, pages 107-115.
Read now
Read now
Paschalis Steiropoulos, Kostas Archontogeorgis, Evangelia Nena & Demosthenes Bouros. (2014) New developments in the management of COPD: clinical utility of indacaterol 75 μg. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 1-7.
Read now
Read now
Daniel Langer, Casey E Ciavaglia, J Alberto Neder, Katherine A Webb & Denis E O’Donnell. (2014) Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Review of Respiratory Medicine 8:6, pages 731-749.
Read now
Read now
Muhammad Ahsan Zafar, Christopher Droege, Madeline Foertsch & Ralph J Panos. (2014) Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs 23:12, pages 1687-1701.
Read now
Read now
Andrea Rossi & Guido Polese. (2013) Indacaterol: a comprehensive review. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 353-363.
Read now
Read now
Anthony D'Urzo & Claus Vogelmeier. (2012) Future of chronic obstructive pulmonary disease management. Expert Review of Respiratory Medicine 6:3, pages 285-299.
Read now
Read now
Paschalis Steiropoulos, Nikolaos Papanas, Evangelia Nena & Demosthenes Bouros. (2012)
Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 13:7, pages 1015-1029.
Read now
Read now
Charlotte Suppli Ulrik. (2012) Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 673-678.
Read now
Read now
Kai M Beeh, Dave Singh, Lilla Di Scala & Anton Drollmann. (2012) Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 503-513.
Read now
Read now
Articles from other publishers (33)
Tanya Palmer, Steven J. Obst, Craig R. Aitken, James Walsh, Surendran Sabapathy, Lewis Adams & Norman R. Morris. (2023) Fixed-intensity exercise tests to measure exertional dyspnoea in chronic heart and lung populations: a systematic review. European Respiratory Review 32:169, pages 230016.
Crossref
Crossref
Andriana I Papaioannou, Evangelia Fouka, Evangelia Nena, Petros Bakakos & Paschalis Steiropoulos. (2022) Patient-Reported Outcome Measurements in Patients with COPD-Obstructive Sleep Apnea Overlap Syndrome: Time for Action?. Journal of Personalized Medicine 12:12, pages 1951.
Crossref
Crossref
Jinping Zheng, Simonetta Baldi, Li Zhao, Huiping Li, Kwan-Ho Lee, Dave Singh, Alberto Papi, Frédérique Grapin, Alessandro Guasconi & George Georges. (2021) Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respiratory Research 22:1.
Crossref
Crossref
Kathryn M. Milne, Nicolle J. Domnik, Devin B. Phillips, Matthew D. James, Sandra G. Vincent, J. Alberto Neder & Denis E. O'Donnell. (2020) Evaluation of Dynamic Respiratory Mechanical Abnormalities During Conventional CPET. Frontiers in Medicine 7.
Crossref
Crossref
François Maltais, Denis E. O’Donnell, Alan Hamilton, Yihua Zhao & Richard Casaburi. (2020)
Comparative measurement properties of constant work rate cycling and the endurance shuttle walking test in COPD: the TORRACTO
®
clinical trial
. Therapeutic Advances in Respiratory Disease 14, pages 175346662092685.
Crossref
Crossref
Fabiano Di Marco, Giovanni Sotgiu, Pierachille Santus, Denis E. O’Donnell, Kai-Michael Beeh, Simone Dore, Maria Adelaide Roggi, Lisa Giuliani, Francesco Blasi & Stefano Centanni. (2018) Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respiratory Research 19:1.
Crossref
Crossref
Denis E. O'Donnell, Amany F. Elbehairy, Danilo C. Berton, Nicolle J. Domnik, Katherine A. Webb & J. Alberto Neder. 2018. Clinical Exercise Testing. Clinical Exercise Testing
235
250
.
In Ae Kim, Yong Bum Park & Kwang Ha Yoo. (2018) Pharmacotherapy for chronic obstructive pulmonary disease. Journal of the Korean Medical Association 61:9, pages 545.
Crossref
Crossref
M. Alfonso, V. Bustamante, P. Cebollero, M. Antón, S. Herrero & J.B. Gáldiz. (2017) Assessment of dyspnea and dynamic hyperinflation in male patients with chronic obstructive pulmonary disease during a six minute walk test and an incremental treadmill cardiorespiratory exercise test. Revista Portuguesa de Pneumologia (English Edition) 23:5, pages 266-272.
Crossref
Crossref
Denis E. O’Donnell, Amany F. Elbehairy, Katherine A. Webb & J. Alberto Neder. (2017) The Link between Reduced Inspiratory Capacity and Exercise Intolerance in Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society 14:Supplement_1, pages S30-S39.
Crossref
Crossref
Henrik Watz, Claudia Mailänder, Monika Baier & Anne Kirsten. (2016) Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Danilo Cortozi Berton, ?lvaro Huber dos Santos, Ivo Bohn Jr., Rodrigo Quevedo de Lima, Vanderl?ia Breda & Paulo Jos? Zimermann Teixeira. (2016) Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study. Jornal Brasileiro de Pneumologia 42:5, pages 367-373.
Crossref
Crossref
Luis Puente-Maestu, Paolo Palange, Richard Casaburi, Pierantonio Laveneziana, François Maltais, J. Alberto Neder, Denis E. O'Donnell, Paolo Onorati, Janos Porszasz, Roberto Rabinovich, Harry B. Rossiter, Sally Singh, Thierry Troosters & Susan Ward. (2016) Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. European Respiratory Journal 47:2, pages 429-460.
Crossref
Crossref
Bruno-Pierre Dubé, Antoine Guerder, Capucine Morelot-Panzini & Pierantonio Laveneziana. (2016) The clinical relevance of the emphysema-hyperinflated phenotype in COPD. COPD Research and Practice 2:1.
Crossref
Crossref
Yin-Yin Qin, Rui-Fa Li, Guo-Feng Wu, Zheng Zhu, Jie Liu, Cheng-Zhi Zhou, Wei-Jie Guan, Jia-Ying Luo, Xin-Xin Yu, Yang-Ming Ou, Mei Jiang, Nan-Shan Zhong & Yuan-Ming Luo. (2015) Effect of tiotropium on neural respiratory drive during exercise in severe COPD. Pulmonary Pharmacology & Therapeutics 30, pages 51-56.
Crossref
Crossref
James B Geake, Eli J Dabscheck, Richard Wood-Baker & Christopher J Cates. (2015)
Indacaterol, a once-daily beta
2
-agonist, versus twice-daily beta
2
-agonists or placebo for chronic obstructive pulmonary disease
. Cochrane Database of Systematic Reviews 2017:3.
Crossref
Crossref
Jinkyeong Park, Jung Su LeeChinkook Rhee & Yeon-Mok Oh. (2015) Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials. Journal of Korean Medical Science 30:10, pages 1453.
Crossref
Crossref
Donald A. Mahler & Denis E. O'Donnell. (2015) Recent Advances in Dyspnea. Chest 147:1, pages 232-241.
Crossref
Crossref
Henrik Watz, Felix Krippner, Anne Kirsten, Helgo Magnussen & Claus Vogelmeier. (2014) Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulmonary Medicine 14:1.
Crossref
Crossref
Lorraine Murphy, Stephen Rennard, James Donohue, Mathieu Molimard, Ronald Dahl, Kai-Michael Beeh, Juergen Dederichs, Hans-Jürgen Fülle, Mark Higgins & David Young. (2014) Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD. Drugs 74:14, pages 1635-1657.
Crossref
Crossref
Amadeu Gavaldà, Israel Ramos, Carla Carcasona, Elena Calama, Raquel Otal, José Luis Montero, Sonia Sentellas, Monica Aparici, Dolors Vilella, Joan Alberti, Jorge Beleta & Montserrat Miralpeix. (2014) The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulmonary Pharmacology & Therapeutics 28:2, pages 114-121.
Crossref
Crossref
Kai-Michael Beeh, Stephanie Korn, Jutta Beier, Dalal Jadayel, Michelle Henley, Peter D'Andrea & Donald Banerji. (2014) Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respiratory Medicine 108:4, pages 584-592.
Crossref
Crossref
Wanzhen Yao, Changzheng Wang, Nanshan Zhong, Xiaowen Han, Changgui Wu, Xixin Yan, Ping Chen, Wei Yang, Michelle Henley & Benjamin Kramer. (2014) Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study. Respirology 19:2, pages 231-238.
Crossref
Crossref
Jutta Beier & Kai M. Beeh. 2014. Indacaterol. Indacaterol
67
76
.
Jiangna Han, Lu Dai & Nanshan Zhong. (2013) Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulmonary Medicine 13:1.
Crossref
Crossref
C. Compton, D. McBryan, E. Bucchioni & F. Patalano. (2013) The Novartis view on emerging drugs and novel targets for the treatment of chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics 26:5, pages 562-573.
Crossref
Crossref
Fa-Ming Jiang, Zong-An Liang, Qiao-Ling Zheng, Rong-Chun Wang, Jian Luo & Chun-Tao Li. (2013) Safety and Efficacy of 12-Week or Longer Indacaterol Treatment in Moderate-to-Severe COPD Patients: A Systematic Review. Lung 191:2, pages 135-146.
Crossref
Crossref
Donald P Tashkin. (2013) Tiotropium for the treatment of chronic obstructive pulmonary disease. Clinical Practice 10:2, pages 141-155.
Crossref
Crossref
Mike Thomas, Marc Decramer & Denis E O'Donnell. (2013) No room to breathe: the importance of lung hyperinflation in COPD. Primary Care Respiratory Journal 22:1, pages 101-111.
Crossref
Crossref
Edward M. Kerwin & James Williams. (2013) Indacaterol 75 µg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective. Therapeutic Advances in Respiratory Disease 7:1, pages 25-37.
Crossref
Crossref
Stan EjioforAlice M. Turner. (2013) Pharmacotherapies for COPD. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 7, pages CCRPM.S7211.
Crossref
Crossref
R. M. Mroz, L. Minarowski & E. Chyczewska. 2013. Respiratory Regulation - The Molecular Approach. Respiratory Regulation - The Molecular Approach
23
28
.
Kate McKeage. (2012) Indacaterol. Drugs 72:4, pages 543-563.
Crossref
Crossref